Dosing and uses of Plasma Plex, Plasmanate (plasma protein fraction)
Adult dosage forms and strengths
injectable solution
- 5%
Treatment of Shock
250-500 mL (12.5-25 g of protein) IV PRN based on response
Monitor for signs of hypervolemia
Hypovolemia
250-500 mL (12.5-25 g of protein) IV PRN based on response
Pediatric dosage forms and strengths
injectable solution
- 5%
Treatment of Shock
Safety & efficacy not established; useful in infants & small children for initial treatment of shock resulting from dehydration & infection
6.6-33 mL/kg (0.33-1.65 g/kg of protein) IV infusion at 5-10 mL/min PRn
Monitor: signs of hypervolemia
Geriatric dosage forms and strengths
Treatment of shock
250-500 mL (12.5-25 g of protein) IV PRN based on response
Monitor for signs of hypervolemia
Hypovolemia
250-500 mL (12.5-25 g of protein) IV PRN based on response
Plasma Plex, Plasmanate (plasma protein fraction) adverse (side) effects
Frequency not defined
Hypotension
Anaphylaxis
Dyspnea
Pulm. edema
Flushing
Tachycardia
Erythema
Urticaria
N/V
Chills
Fever
Headache
Back pain
Hypersalivation
Warnings
Contraindications
Hypersensitivity to albumin, severe anemia, CHF, increases intravascular volume
Hypoproteinemia associated with chronic nephrosis, chronic cirrhosis, malabsorption, protein-losing enteropathies, pancreatic insufficiency, and malnutrition
Patients undergoing cardiopulmonary bypass
Cautions
Allergy to corn, liver disease, renal impairment
Risk of pulmonary edema or CHF
Ineffective in chronic cases of nephrosis, cirrhosis, malabsorption, enteropathies
Pregnancy and lactation
Pregnancy category: C
Lactation: not known if distributed into breast milk, avoid
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Plasma Plex, Plasmanate (plasma protein fraction)
Mechanism of action
Replacement of plasma protein
Pharmacokinetics
Half-Life: 15-20 d
Administration
IV Compatibilities
Whole blood, packed red blood cells, standard carbohydrate & electrolyte solutions
IV Incompatibilities
Protein hydrolysates, solutions containing alcohol, norepinephrine
IV Administration
Infuse at rate PRN NMT 5-8 mL/min
Peds: IV infuse at 5-10 mL/min
Storage
Store at room temperature (NMT 30°C)
Do not freeze
Do not use if protein colloid appears turbid, vial is damaged or if 4 hr passed since container was first entered
